Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs.
Rossanna C PezoAndrew T YanCraig EarleKelvin K ChanPublished in: Heart (British Cardiac Society) (2019)
Our study highlights common use of QT-prolonging drugs and underuse of ECG in oncology patients. Since ECG is an inexpensive, non-invasive and widely available test, it may be readily incorporated in the monitoring of patients for toxicities in routine clinical practice.